Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
42

Recommended

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

ChatGPT and large language models should be a tailwind for this company.

Simonelle Mody | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,006.40	19.00	-0.21%
CAC 40	8,136.32	91.00	-1.11%
DAX 40	24,067.93	87.52	-0.36%
Dow JONES (US)	49,310.32	179.71	-0.36%
FTSE 100	10,380.00	77.01	-0.74%
HKSE	25,978.07	62.87	0.24%
NASDAQ	24,438.50	219.06	-0.89%
Nikkei 225	59,716.18	575.95	0.97%
NZX 50 Index	12,874.94	9.99	-0.08%
S&P 500	7,108.40	29.50	-0.41%
S&P/ASX 200	8,786.50	12.10	-0.14%
SSE Composite Index	4,079.90	13.35	-0.33%